Celgene is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of serious diseases. Established in 1986 and based in Summit, New Jersey, Celgene has made significant strides in areas such as oncology, immunology, and hematology. The company is best known for its flagship products, which have transformed the treatment landscape for patients with cancer and immune disorders.
Celgene emphasizes research and development, with a robust pipeline that includes new treatments aimed at tackling conditions like multiple myeloma and various types of lymphoma. Its commitment to science and patient care is reflected in its cutting-edge facilities and collaboration with leading research institutions.
In 2019, Celgene was acquired by Bristol-Myers Squibb, merging their expertise to enhance the development of life-saving medications. The Celgene logo, which symbolizes their dedication to pioneering healthcare solutions, continues to be recognized in the industry for its association with innovation and quality.
With a patient-centric approach, Celgene strives to improve the lives of those battling complex diseases, reaffirming its position as a leader in the biopharmaceutical sector through ongoing commitment to research and patient advocacy.
